90 million upfront for a drug that doesn't even have phase II data yet. Color me shocked as I did not think they would get anything near this sum, especially given the limited data at hand.
Friedman's performance this year has been quite impressive.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.